雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

Brain and Nerve No to Shinkei Volume 19, Issue 7 （July 1967）

Brain and Nerve 脳と神経 19巻7号（1967年7月発行）

Japanese English

研究

メトラゾールとメジマイドとの発作波賦活における特異性—基礎的研究ならびに臨床使用経験 CHARACTERISTICS OF METRAZOL AND MEGIMIDE FOR ACTIVATION OF SEIZURE DISCHARGE:Analyses of Cat Experiment and Human Activation 六川二郎 ¹ , 早川徹 ¹ , 中谷進 ¹ , 岩田吉一 ¹ , 小林清史 ¹ Jiro MUKAWA ¹ , Tohru HAYAKAWA ¹ , Susumu NAKATANI ¹ , Kazuyoshi IWATA ¹ , Kiyofumi KOBAYASHI ¹ ¹大阪大学医学部陣内外科 ¹Department of Neurosurgery, Medical School, Osaka University pp.671-675

発行日 1967年7月1日 Published Date 1967/7/1

DOI https://doi.org/10.11477/mf.1406202239

PDF(4188KB)

有料閲覧

Abstract 文献概要
1ページ目 Look Inside

I．緒論

　1935年v．Meduna^9）によつて紹介されたメトラゾールと，1954年Shaw et al．^8）によつて紹介されたメジマイドとは，ともに現在実験てんかん痙攣誘発剤としてまたは異常脳波賦活剤として賞用されている。

　各種刺激剤に対して，脳内諸機構はその生理解剖学的な特異性によつて異なつた感受性を有し，異なつた反応態度を示すと考えられるので，両剤の誘発様式に差がありうるだろうし，またてんかん脳のごとき器質的機能的に異常な脳ではさらにその反応態度は異なつてくると想像される。

(1) In order to make a comparison of Metrazol and Megimide for inducing seizure discharges, each of these was intravenously given in unanesthetized cats. Thedosage was 10 mg and 2.5 mg/30 sec for Metrazol and Megimide respectively.

a) Body weight should be considered as a significant factor for threshold determination.

b) The minimum dosage and minimum injection times for inducing major seizure were 22.5 mg/kg and 6.3, for Metrazol and 10.0 mg/kg and 11 for Meg-imide respectively.

c) From the standpoint of EEG discharge, Metrazol seizure was of subcortical origin and Megimide seizure was of cortical origin.

(2) Statistical analysis was made in activation of sei-zure discharge of human epileptic and non-epileptic patients who showed no seizure discharge in routine EEG examination. The intravenously given dosage was 1 mg and 0.25 mg/kg/min for Metrazol and Megimide respectively.

a) In epileptic group, more than 90% of activation was obtained by 7 injection times of Metrazol (7 mg/kg in total), and, in contrast, by over 11 injection times of Megimide (over 2.75 mg/kg in total).

b) In non-epileptic group, though all of them had a certain anamnesis of head trauma or neurological symptoms, each of these two dosage induced more than 30% of seizure discharge activation.

c) Both in epileptic and non-epileptic groups, Metrazol tended to activate bilateral diffuse seizure dis-charges more than localized discharges based on the analysis of their threshold and numbers of activation. Vice versa in Megimide.

(3) It is to be stressed that these characteristics of Metrazol and Megimide for activation of seizure dis-charge and pharmacological values were consistent ir-respective of species difference between cat and human, and pathological difference between epileptic and non-epileptic patients.